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The utility of genome editing technologies for dis-
ease modeling and developing cellular therapies
has been extensively documented, but the impact
of these technologies on mutational load at the
whole-genome level remains unclear. We performed
whole-genome sequencing to evaluate the muta-
tional load at single-base resolution in individual
gene-corrected human induced pluripotent stem
cell (hiPSC) clones in three different disease models.
In single-cell clones, gene correction by helper-
dependent adenoviral vector (HDAdV) or Transcrip-
tion Activator-Like Effector Nuclease (TALEN)
exhibited few off-target effects and a low level of
sequence variation, comparable to that accumulated
in routine hiPSC culture. The sequence variants were
randomly distributed and unique to individual clones.
We also combined both technologies and developed
a TALEN-HDAdV hybrid vector, which significantly
increased gene-correction efficiency in hiPSCs.
Therefore, with careful monitoring via whole-genome
sequencing it is possible to apply genome editing to
human pluripotent cells with minimal impact on
genomic mutational load.The combination of stem cells and targeted genome editingprovides a powerful tool to model human disease and develop
curative cellular therapies for genetic disorders. Custom-designed nucleases, including Zinc Finger Nucleases (ZFNs),
Transcription Activator-Like Effector Nucleases (TALENs) and
Clustered Regularly Interspaced Short Palindromic Repeat
(CRISPR)/CAS9 nucleases, specifically induce double-strand
breaks (DSBs) in the target genomic loci, which facilitate
genome editing by homologous recombination (HR) (Ding
et al., 2013a, 2013b; Hockemeyer et al., 2009; Hou et al.,
2013; Lombardo et al., 2007; Soldner et al., 2011; Zou et al.,
2009). Several strategies have also been developed to allow
efficient HR without inducing DSBs, which could be genotoxic
(Li et al., 2014). Recently, both synthetic nucleases and
nuclease-independent methods (HDAdV and bacteria artificial
chromosomes) have been independently used for targeted
correction of pathogenic mutations of multiple genetic dis-
eases, which results in effective rescue of disease phenotypes
(Corti et al., 2012; Fong et al., 2013; Liu et al., 2011b, 2012;
Reinhardt et al., 2013; Sanders et al., 2014; Yusa et al.,
2011). These and similar studies provide a rationale for applying
genome-editing technologies toward developing novel cellular
therapies for a variety of debilitating genetic disorders.
An important concern that needs to be addressed before
clinical translation of the current targeted gene-correction
approaches is the possibility of unwanted genetic variations
introduced by the gene targeting procedure. HDAdVs are highly
efficient in targeted gene correction in hiPSCs (Li et al., 2011;
Liu et al., 2011a, 2011b, 2012). To determine the mutation
frequency associated with this method, we first performed
deep and pairwise whole-genome sequencing (WGS) to assess
DNA sequence variation in disease-specific hiPSCs derived
from Hutchinson-Gilford progeria syndrome (HGPS), sickle cell
disease (SCD), and Parkinson’s disease (PD) after gene correc-
tion by HDAdV (groups 1–3, Figure 1A).Cell Stem Cell 15, 31–36, July 3, 2014 ª2014 Elsevier Inc. 31
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Figure 1. Relationship between Gene-Corrected Clones and Their Parental Lines
(A) Parental disease iPSC lines were genetically corrected by HDAdV or TALEN. During the gene-correction process, neomycin-resistant colonies were isolated
and gene-correction events were determined by genotyping. Identified gene-corrected clones were expanded and genomic DNA was extracted for WGS at
day 80. The neomycin-resistance cassette was removed by FLPo recombinase, and Neo-removed clones were expanded and genomic DNA was extracted for
WGS at day 150 to 180. The results of WGS analysis were compared between each parental line and its genetically modified clone to determine mutations
accumulated during the entire process.
(B) Gene-targeting and gene-correction efficiencies at theHBB locus with TALEN, HDAdV, CRISPR/CAS9 nuclease, and the TALEN-HDAdV combination vector
(telHDAdV).
Group 1: HGPS disease iPSC line (HGPS) and its gene-corrected clone by HDAdV (cHGPS) were published previously (Liu et al., 2011a, 2011b). Group 2: SCD
disease iPSC line (SCD) and its gene-corrected clone by HDAdV (cSCD) were published previously (Li et al., 2011). Group 3: PD disease iPSC line (PD) and its
gene-corrected clone by HDAdV (cPD) were published previously (Liu et al., 2012). Group 4: The single-cell-derived SCD disease iPSC clone (SCD-ref) was
genetically corrected by HDAdV or TALEN. HDAdV1 and TALEN1 target intron 1 of theHBB gene. HDAdV2 and TALEN2 target downstream of theHBB gene. The
unmodified clone (SCD-ctrl) was used as a strict control. See also Figure S1.
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WGS in Gene-Corrected iPSC ClonesWe generated on average 603 coverage WGS data
(Table S1A). At this depth, greater than 99% (Table S1A)
of the bases were sufficiently covered to pass our thresholds
for variant calling (Cheng et al., 2012). With stringent
criteria to eliminate bias from the sequencing process, we
discovered 452, 440, and 665 single nucleotide variants
(SNVs) when comparing cHGPS-iPSCs, cSCD-iPSCs, and
cPD-iPSCs to their corresponding reference lines, respectively
(Table 1). We also observed on average 471 loss-of-heterozy-32 Cell Stem Cell 15, 31–36, July 3, 2014 ª2014 Elsevier Inc.gosity (LOH) variants per genome in gene corrected cells
(Table 1).
Our analysis initially detected a large number of small inser-
tions and deletions (indels) (average 892, range: 892–1,052) in
all cases. However, Sanger sequencing of indel candidates in
exonic regions and in an additional 35 random loci showed
that all of them were false positives. The high false positive
rate of indel calling has been reported by others and likely repre-
sents a common technical difficulty associated with current
Table 1. Sequence Variants in the Gene-Corrected iPSC Clones by WGS Analysis
Group 1 2 3 4
reference sample HGPS SCD PD SCD-ref SCD-ref SCD-ref SCD-ref SCD-ref
analyzed sample cHGPS cSCD cPD SCD-ctrl cSCD-
HDAdV1
cSCD-
HDAdV2
cSCD-
TALEN1
cSCD-
TALEN2
Number of SNVs total (estimateda) 452 (373) 440 (363) 665 (549) 90 (82) 129 (118) 103 (94) 74 (67) 98 (89)
intergenic 294 270 390 56 69 57 46 57
intronic 131 149 231 29 51 38 27 34
exonic 7 5 8 0 3 1 0 1
UTRs 2 5 7 1 1 0 0 0
ncRNA 9 5 22 3 3 6 0 2
up/downstreamb 9 6 7 1 2 1 1 4
Number of LOHs total 121 402 899 149 159 165 134 157
intergenic 72 265 584 83 95 90 75 94
intronic 44 115 262 60 56 68 49 54
exonic 3 7 12 1 0 0 1 0
UTRs 0 1 8 2 0 0 4 2
ncRNA 1 9 24 1 6 3 3 4
up/downstreamb 1 5 9 2 2 4 2 3
Number of indels total (validatedc) 78 72 55 33 (3) 53 (1) 64 (4) 40 (4) 48 (2)
intergenic (validatedc) 38 (N.D.) 31 (N.D.) 28 (N.D.) 20 (2) 31 (0) 29 (0) 21 (0) 27 (1)
intronic (validatedc) 28 (N.D.) 29 (N.D.) 19 (N.D.) 10 (0) 15 (1) 28 (2) 15 (2) 16 (1)
exonic (validatedc) 2 (0) 1 (0) 2 (0) 0 2 (0) 2 (0) 0 0
UTRs (validatedc) 2 (N.D.) 3 (N.D.) 2 (N.D.) 2 (1) 2 (0) 3 (2) 1 (1) 1 (0)
ncRNA (validatedc) 4 (N.D.) 6 (N.D.) 1 (N.D.) 0 3 (0) 1 (0) 2 (1) 2 (0)
up/downstreamb (validatedc) 4 (N.D.) 2 (N.D.) 3 (N.D.) 1 (0) 0 1 (0) 1 (0) 2 (0)
SNVs, single-nucleotide variations; LOHs, loss of heterozygosities; indels, insertions or deletions; N.D., not determined. See also Table S1.
aEstimated total SNVs and indels in whole genome calculated by validation results.
bDefined as 1 kb away from transcription start site or transcription end site.
cValidated number by Sanger sequencing.
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WGS in Gene-Corrected iPSC ClonesWGS technology (Goldstein et al., 2013; Young et al., 2012).
Subsequent analysis allowed us to filter out most of the false
positive candidates and improve the estimate of the number of
real indels (Table 1; see below and Supplemental Experimental
Procedures).
The results from the aforementioned cell lines showed a
relatively high incidence of sequence variants per sample
and big sample-to-sample variation. These observations could
be due to the fact that the group 1–3 samples were bulk
passaged and the pairs of lines being compared were not
passaged in parallel. In vitro passaging induces mutations
and contributes to genetic heterogeneity of hiPSCs (Ji et al.,
2012), but heterogeneity in bulk culture iPSCs can be reduced
by single-cell subcloning (Sugiura et al., 2014). Our own evalu-
ations have also indicated greater overall variation in bulk-
passaged lines relative to an hg19 reference genome than in
single-cell subclones (data not shown). We therefore evaluated
whether our analysis could be further improved by (1) maintain-
ing the reference cell lines in parallel with cells undergoing gene
correction; (2) using single-cell-derived clones to minimize
preexisting genetic heterogeneity; or (3) including additional
gene-corrected clones generated using alternative methods
to evaluate the contribution to the mutational load by these
factors.To this end we performed gene-correction experiments de
novo in the SCD context using nuclease-independent (HDAdV)
and nuclease-based (TALEN) methods. All samples in this group
(group 4) started from a single-cell-derived and integration-free
SCD-iPSC clone (Li et al., 2011), which was also maintained
without genetic manipulation in parallel with gene-targeted lines
as an unmodified control (cHBB-ctrl). We designed two indepen-
dent TALEN expression vectors that target exon 2 (TALEN1) and
a downstream region of the HBB locus (TALEN2), respectively
(Figure S1A available online). The efficacy of the TALENs was
confirmed by Surveyor assay in HEK293 cells (Figure S1B). For
TALEN-mediated gene correction, an HR donor vector was
also used (Figures S1C and S1D). Additionally, we performed
gene targeting using two independent HDAdV-based gene-
correction vectors (HDAdV1 and HDAdV2), one of which was
described previously (Li et al., 2011) (Figures S1E and S1F).
The TALENs and HDAdVs mediated gene-correction with com-
parable efficiencies per integration at the HBB locus (Figure 1B).
Validated gene-corrected clones (cHBB-TALEN1, cHBB-
TALEN2, cHBB-HDAdV1, and cHBB-HDAdV2) were subjected
to deep WGS (coverage: 56.3–66.43, 99.15%–99.20% of the
bases, Figure 1A, Figures S1G and S1H, and Table S1A). Since
group 4 TALEN- and HDAdV-mediated gene-corrected clones
and unmodified clone showed substantially fewer SNVsCell Stem Cell 15, 31–36, July 3, 2014 ª2014 Elsevier Inc. 33
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WGS in Gene-Corrected iPSC Clones(range: 74–129) compared to groups 1–3 (Table 1) and less vari-
ation in SNV numbers between samples, we focused on group 4
in subsequent analyses.
To independently validate the SNVs, we obtained high quality
Sanger sequencing data for the 105 SNVs in unmodified cells.
Eighty-two percent of the sites contained the annotated muta-
tion (Table 1). We calculated the number of predicted SNVs in
all of the analyzed clones in group 4 (range: 67–118) as well as
in groups 1–3 (range: 363–549). Importantly, regardless of tar-
geting vector design and methodology, there was no dramatic
increase of SNVs in gene-corrected clones compared with
the control line (Table 1). Additionally, HDAdV and TALEN
approaches resulted in comparable numbers of SNVs (Table 1).
On average, 83 SNVs were introduced per genome after gene
correction. This number is significantly smaller than the number
of SNVs (over 1,000) reported to accumulate during somatic cell
reprogramming (Cheng et al., 2012). There was no specific chro-
mosomal region or functional pathway that showed significant
enrichment and none of the variants were common to all samples
(data not shown).
The majority of the samples in group 4 did not contain any
exonic SNVs. Two gene-corrected clones—cSCD-HDAdV1
and cSCD-TALEN2—contained three and one validated exonic
SNVs, respectively (Table S1B). Among them, two were nonsy-
nonymous changes. Based on Polyphen2 (Adzhubei et al.,
2010), the missense mutation in the CBX2 gene is predicted to
be benign, while the one in the AMBP gene is potentially
damaging. However, given the heterozygous nature of these
SNVs, the potential harm caused by the mutations could be miti-
gated by the presence of a wild-type allele.
We next sought to understand the functional relevance of
the noncoding SNVs found in our samples (Table S1C). We
compared all 489 noncoding SNVs in group 4 with a catalog of
12,345 single-nucleotide polymorphisms (SNPs) identified in
1,791 Genome-Wide Association Studies (GWAS) published to
date and found zero overlap. Similarly, none of the SNVs were
found in the catalog of somatic mutations in cancer (Forbes
et al., 2008). Low numbers of SNVs were found to overlap with
potential regulatory elements such as promoter CpG islands,
ENCODE DNaseI hypersensitive sites, and conserved regions
in vertebrates. Together, although the functional impact of non-
coding SNVs is difficult to ascertain, these results indicate that
targeted gene correction by HDAdVs or TALENs did not intro-
duce more SNVs above the background level of the unmodified
control and that it should be possible to avoid clones that bear
harmful mutations for downstream applications, especially
considering the heterozygous nature of the SNVs.
LOH has been commonly reported in genomic sequencing of
tumor samples (Ha et al., 2012). We noted big variations in LOH
number in groups 1–3, which might be attributed to their distinct
genetic/disease background. In contrast, LOHnumber in group 4
was consistently and significantly lower than that of group 2,
which shared the same genetic background as group 4 (Table
1). All of the LOH variants observed in protein-coding genes
matched one of the parental chromosome DNA sequences.
To estimate the number of true indels in the genome, we per-
formed Sanger sequencing for all of the 327 indels detected in
SCD-ctrl. Out of 208 successful assays, two (0.96%) showed
concordant indels as predicted. Based on this analysis, we34 Cell Stem Cell 15, 31–36, July 3, 2014 ª2014 Elsevier Inc.generated a new filter that removed most false positive indel
calls and therefore enriched the true indels by about 10-fold
(see Supplemental Experimental Procedures). We then per-
formed Sanger sequencing for all of the indel candidates and
concluded that the occurrence of novel indels in gene-corrected
clones was low (one to four per genome) and not above the
background level observed in the unmodified control line (Table 1
and Table S1D). Additionally, we compared all indels and LOHs
with known disease-associated SNPs and found no overlap
(data not shown).
We identified 40 SNV candidates that appeared in at least
two of the eight lines of groups 1–4. After PCR and Sanger
sequencing, no common SNV was found among all of the
gene-corrected and uncorrected clones. Similarly, there were
no common indels among groups 1–4. This result suggests
that mutations are induced in a random manner.
To understand the extent of large insertions and deletions that
may not be detected by the indel-calling algorithm, we per-
formed structure variation (SV) analysis by CREST (Wang et al.,
2011). Six SVs ranging from 187 bp to 1,581 kbp were
detected and further validated by PCR/Sanger sequencing.
Importantly, five of seven gene-corrected clones did not show
any structure variance (Table S1E). We also found that there is
only one SV in the case of TALEN1, and that it is far from any pre-
dicted off-target sites, suggesting no relationship between SVs
and TALEN off-target sites (Tables S1D and S1E, and see
below).
We looked for evidence of TALEN-induced off-target muta-
tions near potential off-target sites (20,542 for TALEN1 and
29,026 for TALEN2; see Supplemental Experimental Proce-
dures) predicted by TALENoffer in cHBB-TALEN1 and cHBB-
TALEN2 iPSCs. Of note, the performance of TALENoffer has
been validated recently (Guilinger et al., 2014; Liu et al., 2014;
Miyaoka et al., 2014). We found no incidence of the typical
>2 bp indel near predicted spacer regions in either TALEN cor-
rected line (Table S1D). DSB-induced recombination in eukary-
otes is also known to result in a 100- to 1,000-fold increase in
the mutation rate near the DSB (Holbeck and Strathern, 1997;
Rattray et al., 2002; Strathern et al., 1995). Among all of the
SNVs and indels, three SNVs were found within 1,000 bp of a
predicted off-target site only in cSCD-TALEN2 (Table S1D).
Although it is possible that these SNVs were caused by a
TALEN-mediated DSB-associated point mutation, further evi-
dence is necessary to support this hypothesis.
Given that WGS analysis showed that both HDAdV and
TALEN approaches did not significantly elevate mutational
burden in gene-corrected hiPSCs, we hypothesized that the
combination of these two methods could result in a more robust
gene-editing tool that would not sacrifice genome integrity.
Accordingly, we created an HDAdV vector (HBB-c-telHDAdV)
harboring both HBB-specific long homology arms (13.3 kb)
and TALEN expression cassettes (Figures S1I and S1J).
The use of this hybrid vector (hereafter called telHDAdV) re-
sulted in significantly higher genome-editing efficiency when
compared with either single vector (up to 12.5-fold if calculated
per drug resistant colony or up to 30-fold if calculated per cell;
Figure 1B and Figure S1K). Recently, CRISPR/CAS9 nucleases
have been shown to outperform TALENs in editing the same loci
in hPSCs (Ding et al., 2013b). To compare the performance of
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WGS in Gene-Corrected iPSC ClonesCRISPR/CAS9 nucleases and telHDAdVs, we designed two
CRISPR/CAS9 nucleases targeting the same loci as the TALENs
encoded by the telHDAdVs (Figure S1A). The gene targeting
efficiency of these CRISPR/CAS9 nucleases was on par with
the corresponding TALENs at the HBB locus (Figure 1B and Fig-
ure S1K). Interestingly, a recent report also showed that
although CRISPR/CAS9 nucleases are more efficient in NHEJ
mutagenesis than TALENs at the HBB locus, these methods
are comparable in terms of homology-directed repair (Hendel
et al., 2014). Importantly, telHDAdVs showed clear superiority
over both CRISPR/CAS9 nucleases and TALENs in gene target-
ing and gene correction of the HBB locus (Figure 1B and Fig-
ure S1K). These results show that the combination of the
nuclease-dependent and -independent techniques may con-
stitute a productive strategy to optimize genome-editing
approaches.
Finally, we performed Sanger sequencing to determine if the
hybrid vector-corrected lines share any common nucleotide var-
iations with the lines corrected with the corresponding TALENs
or HDAdVs (Table S1D). No common SNV/indel was found be-
tween the HDAdV- and telHDAdV-corrected lines among 51
validated variants. Two SNVs out of thirty-five validated SNVs/
indels in the TALEN1-corrected line were found in telHDAdV1-
corrected cells. Similarly, 1 of the 32 validated SNVs/indels
was shared between TALEN2- and telHDVAdV2-corrected lines.
Because these common SNVs between TALEN- and telHDAdV-
corrected clones were not found elsewhere, they are likely to be
due to off-target effects of the TALENs. However, all of the
common mutations are far away from any predicted TALEN
off-target sites (range: 17–249 kb; Table S1D). It is possible, as
it has been previously reported with ZFNs (Gabriel et al., 2011;
Pattanayak et al., 2011), that these mutations are near cryptic
off-target sites that are not predicted in silico. Thus, while we
did not find mutations specifically associated with HDAdV, our
results suggest that TALEN might induce rare SNVs in a
nonrandom manner.
In summary, our study provides evidence that HDAdV- or
TALEN-mediated genome editing results in low levels of
sequence variants in single-cell clones, which are not signifi-
cantly different from what is observed during routine hiPSC cul-
ture. Our WGS analysis of TALEN-edited hiPSCs shows no clear
evidence of widespread off-target modification. Interestingly,
analysis of the telHDAdV-corrected clones revealed rare SNVs
that were also in TALEN-corrected clones and were far from
any predicted off-target sites, suggesting a need for improve-
ment in off-target site prediction. Our findings only cover
TALENs of a 20 + 20 configuration, and the specificity of TALENs
is sensitive to the length of the TALE recognition sites (Guilinger
et al., 2014; Liu et al., 2014; Miyaoka et al., 2014). Additionally,
our analysis of off-target effects is broad but limited in depth,
so it is very likely and in fact expected that other low-frequency
off-target effects are not detected due to the small sample
number.
In sum, therefore, it seems reasonable to conclude that the
mutational load attributable to genome editing technologies in
single-cell clones can be minimal and should not constitute an
inherent obstacle for future application of single-cell clone-
based gene editing approaches in human regenerative medi-
cine. In addition, the development of combined strategies suchas the hybrid gene-editing vector technology presented here
may further accelerate clinical translation.
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